Ermias GizawDawit Getachew2025-08-072025-08-072024-10-23https://etd.aau.edu.et/handle/123456789/6202Background: Biopsy plays a crucial role in diagnosing musculoskeletal tumors. While open biopsy is traditionally seen as the gold standard, recent literature indicates that percutaneous core needle biopsy yields comparable results while offering benefits such as being less invasive, having fewer complications, and being faster and more cost-effective. This study aims to evaluate and compare the diagnostic accuracy and effectiveness of core needle biopsy against final surgical resection in musculoskeletal lesions. Methods: This retrospective cross-sectional study, conducted from April 2022 to June 2024, identified and enrolled patients with primary bone or soft tissue tumors who underwent core needle biopsy (CNB) followed by tumor resection at the Orthopedics Department of Tikur Anbessa Specialized Hospital. The CNB results were evaluated for sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy. RESULTS: A total of 87 patients were identified and enrolled in this study. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy of the core needle biopsy (CNB) were 90%, 94.6%, 95.7%, and 87.5%, respectively. The overall diagnostic accuracy of CNB was 93.1%. A specific diagnosis was achieved in 80% of the cases (67 out of 87), and no complications were reported associated with the CNB procedure Conclusion: Core needle biopsy is a reliable technique for differentiating benign and malignant as well as obtaining the final diagnosis of primary bone and soft tissue tumors, with a lower risk of complications. It may be confidently integrated into clinical practice as a substitute for the open incisional biopsy method.en-USDiagnostic accuracy of Core needle BiopsyThesis